CARsgen Therapeutics Holdings Limited announced that Dr. Sylvie Peltier has been appointed as Senior Vice President of Global Regulatory Affairs of the Company with effect from October 31, 2022. She will be responsible for developing global regulatory strategies, leading and driving the Company's regulatory affairs activities, and initiatives in support of IND/CTA/BLA filing and approval of developmental products globally. Dr. Peltier has extensive global leadership and hands-on experiences in clinical and CMC regulatory affairs across several multinational pharmaceutical and biopharmaceutical companies.

Prior to joining CARsgen, Dr. Peltier served as Vice President, Head of US Regulatory Affairs at MorphoSys US Inc. since 2020, and as Head of Regulatory Affairs at Servier Pharmaceuticals LLC from 2018. Before joining Servier Pharmaceuticals LLC, Dr. Peltier served at Cephalon since 2007, which was acquired later by TEVA Pharmaceuticals Industries Ltd, holding various positions from Senior Director, Europe Regulatory Affairs, CNS/Pain and CMC, Senior Director, US Regulatory Affairs, to Senior Director, Clinical Search Evaluation and Due Diligence. Previously, Dr. Peltier worked at Pfizer Regulatory Affairs from 1995.

Dr. Peltier earned a Diploma of Pharmacy Doctorate and a Diploma of Graduated Specialized Studies (DESS) in Health Law from University of Paris XI in Paris, France.